CFR getting closer to nabbing Adcock's manufacturing capacity

If Chile's CFR Pharmaceuticals completes its proposed $1.3 billion buyout of South African drugmaker Adcock Ingram, it will pick up needed manufacturing capacity. When the offer was announced last month, CFR said that by filling up excess manufacturing capacity at Adcock Ingram and combining their API purchasing power, they could reduce production costs. The deal is not done, but Adcock said today it is continuing the process even though it has gotten some other offers. The company said it has found them less compelling than the one from CFR. Story | More